IBDEI35K ; ; 04-FEB-2020
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,50342,0)
 ;;=E89.6^^193^2490^29
 ;;^UTILITY(U,$J,358.3,50342,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,50342,1,3,0)
 ;;=3^PostProcedural Adrenocortical Hypofunction
 ;;^UTILITY(U,$J,358.3,50342,1,4,0)
 ;;=4^E89.6
 ;;^UTILITY(U,$J,358.3,50342,2)
 ;;=^5003042
 ;;^UTILITY(U,$J,358.3,50343,0)
 ;;=L68.0^^193^2490^6
 ;;^UTILITY(U,$J,358.3,50343,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,50343,1,3,0)
 ;;=3^Hirsutism
 ;;^UTILITY(U,$J,358.3,50343,1,4,0)
 ;;=4^L68.0
 ;;^UTILITY(U,$J,358.3,50343,2)
 ;;=^5009262
 ;;^UTILITY(U,$J,358.3,50344,0)
 ;;=M80.00XA^^193^2490^2
 ;;^UTILITY(U,$J,358.3,50344,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,50344,1,3,0)
 ;;=3^Age-Related Osteoporosis w/ Fx,Unspec Site,Init Encntr
 ;;^UTILITY(U,$J,358.3,50344,1,4,0)
 ;;=4^M80.00XA
 ;;^UTILITY(U,$J,358.3,50344,2)
 ;;=^5013363
 ;;^UTILITY(U,$J,358.3,50345,0)
 ;;=M81.0^^193^2490^3
 ;;^UTILITY(U,$J,358.3,50345,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,50345,1,3,0)
 ;;=3^Age-Related Osteoporosis w/o Fx
 ;;^UTILITY(U,$J,358.3,50345,1,4,0)
 ;;=4^M81.0
 ;;^UTILITY(U,$J,358.3,50345,2)
 ;;=^5013555
 ;;^UTILITY(U,$J,358.3,50346,0)
 ;;=M85.80^^193^2490^26
 ;;^UTILITY(U,$J,358.3,50346,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,50346,1,3,0)
 ;;=3^Osteopenia,Unspec Site
 ;;^UTILITY(U,$J,358.3,50346,1,4,0)
 ;;=4^M85.80
 ;;^UTILITY(U,$J,358.3,50346,2)
 ;;=^5014473
 ;;^UTILITY(U,$J,358.3,50347,0)
 ;;=N62.^^193^2490^5
 ;;^UTILITY(U,$J,358.3,50347,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,50347,1,3,0)
 ;;=3^Gynecomastia
 ;;^UTILITY(U,$J,358.3,50347,1,4,0)
 ;;=4^N62.
 ;;^UTILITY(U,$J,358.3,50347,2)
 ;;=^5015790
 ;;^UTILITY(U,$J,358.3,50348,0)
 ;;=E66.3^^193^2490^27
 ;;^UTILITY(U,$J,358.3,50348,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,50348,1,3,0)
 ;;=3^Overweight
 ;;^UTILITY(U,$J,358.3,50348,1,4,0)
 ;;=4^E66.3
 ;;^UTILITY(U,$J,358.3,50348,2)
 ;;=^5002830
 ;;^UTILITY(U,$J,358.3,50349,0)
 ;;=E89.1^^193^2490^31
 ;;^UTILITY(U,$J,358.3,50349,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,50349,1,3,0)
 ;;=3^Postprocedural Hypoinsulinemia
 ;;^UTILITY(U,$J,358.3,50349,1,4,0)
 ;;=4^E89.1
 ;;^UTILITY(U,$J,358.3,50349,2)
 ;;=^5003036
 ;;^UTILITY(U,$J,358.3,50350,0)
 ;;=R73.03^^193^2490^33
 ;;^UTILITY(U,$J,358.3,50350,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,50350,1,3,0)
 ;;=3^Pre-Diabetes
 ;;^UTILITY(U,$J,358.3,50350,1,4,0)
 ;;=4^R73.03
 ;;^UTILITY(U,$J,358.3,50350,2)
 ;;=^8295662
 ;;^UTILITY(U,$J,358.3,50351,0)
 ;;=E73.9^^193^2490^18
 ;;^UTILITY(U,$J,358.3,50351,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,50351,1,3,0)
 ;;=3^Lactose Intolerance,Unspec
 ;;^UTILITY(U,$J,358.3,50351,1,4,0)
 ;;=4^E73.9
 ;;^UTILITY(U,$J,358.3,50351,2)
 ;;=^5002914
 ;;^UTILITY(U,$J,358.3,50352,0)
 ;;=H40.9^^193^2491^11
 ;;^UTILITY(U,$J,358.3,50352,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,50352,1,3,0)
 ;;=3^Glaucoma,Unspec
 ;;^UTILITY(U,$J,358.3,50352,1,4,0)
 ;;=4^H40.9
 ;;^UTILITY(U,$J,358.3,50352,2)
 ;;=^5005931
 ;;^UTILITY(U,$J,358.3,50353,0)
 ;;=H26.9^^193^2491^7
 ;;^UTILITY(U,$J,358.3,50353,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,50353,1,3,0)
 ;;=3^Cataract,Unspec
 ;;^UTILITY(U,$J,358.3,50353,1,4,0)
 ;;=4^H26.9
 ;;^UTILITY(U,$J,358.3,50353,2)
 ;;=^5005363
 ;;^UTILITY(U,$J,358.3,50354,0)
 ;;=H10.9^^193^2491^10
 ;;^UTILITY(U,$J,358.3,50354,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,50354,1,3,0)
 ;;=3^Conjunctivitis,Unspec
